A Health Technology Assessment of a Proposed Biosimilar for the Treatment of Chemotherapy Induced Febrile Neutropenia: A U.S. Payer Perspective

he goal of this comparative technology assessment was to estimate the economic value as well as clinical value of a proposed biosimilar from a US payer perspective. The biosimilar is compared to filgrastim and pegfilgrastim, intended for the treatment of chemotherapy induced febrile neutropenia (CIN). A decision analytical model was designed and implemented using TreeAge Pro 2013 software. The initial cost and clinical estimates were based on similar model published by Eldar-Lissai (2008). The model was modified to include a proposed biosimilar expected to be released in the U.S. in 2014. Modified and updated clinical and cost estimates were input into the model and costs were adjusted for 2013 using the CPI for medical care. Costs and outcomes were estimated for a time horizon of one chemotherapy cycle. Sensitivity analyses, including Monte Carlo probabilistic analyses, were conducted to assess the robustness of the model. The model estimated expected costs for the three therapies to be:...